New Summit Bio to be China Partner for Pacgen’s Thrush Treatment

New Summit Biopharma Company of Shanghai has struck a deal with Pacgen Biopharmaceuticals of Vancouver, Canada to develop a treatment for oral candidiasis for commercialization in China. New Summit Bio will collaborate with Pacgen to raise funding and to develop the anti-fungal compound, PAC-113, for China. More details... Stock Symbol: (TSX VENTURE: PGA)